Company / Cash & Equivalents
Vericel Cash & Equivalents History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$100.1M
FY2025
5-year range
$33.6M / $100.1M
FY2021-FY2025
Trend
+34.3%
vs FY2024
Sector context
#140 of 207
Health Care
What the data says
At $100M, Vericel's cash & equivalents ranks #140 of 207 in the Health Care sector. Cash & Equivalents has increased for 6 consecutive years, from $18M in FY2019 to $100M in FY2025.
Based on SEC 10-K filings.
$100M in FY2025 with a 5-year CAGR of +30.1%.
Improved from $69M to $100M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +13.6%
- 5-Year CAGR
- +30.1%
- 10-Year CAGR
- -
Sector benchmark
#140 of 207 in Health CareTop 68% of 207This company $100.1M Sector average $669.5M
▼
-85.0% below sector average
Key checks
Key Insights
- Vericel's cash & equivalents has grown for 6 consecutive years.
- 5-year CAGR of +30.1%, indicating consistent growth.
- In FY2025, cash & equivalents increased 34.3% year-over-year.
- Ranks #140 out of 207 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $100.1M | +34.3% |
| FY2024 | $74.5M | +7.9% |
| FY2023 | $69.1M | +1.1% |
| FY2022 | $68.3M | +103.2% |
| FY2021 | $33.6M | +25.0% |
| FY2020 | $26.9M | +47.0% |
| FY2019 | $18.3M | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026